NCT04437511: A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
- State
- Under way
- Phase
- Phase 3
- People
- 1,736 taking part
- Started
- 19 Jun 2020
- Primary completion
- 14 Apr 2023
- Arms
- Donanemab
- Results
- Posted on the registry
- 18 Jun 2020: Trial registered
- 19 Jun 2020: Trial started
- 20 May 2024: Trial results posted